^
    3ms
    A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P2, N=25, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=124 --> 25 | Recruiting --> Terminated; Adjustment of R&D strategy
    Enrollment change • Trial termination
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020) • SHR-1802
    over2years
    Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study. (PubMed, Ther Adv Med Oncol)
    Further studies with larger sample size and in combination forms are warranted for future clinical application. NCT04414150.
    P1 data • PK/PD data • Journal • Metastases
    |
    SHR-1802
    over2years
    A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=132, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • AiRuiLi (adebrelimab) • SHR-1802
    over3years
    A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P2, N=124, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020) • SHR-1802
    almost4years
    A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P2, N=124, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020) • SHR-1802